If you are an organization content with patient-centric approaches, you are behind. Today it is about patient-driven drug development.
A discussion of the impact of a strategic alliance in to facilitate operational success at the clinical trial site level in Malaysia.
Insights identify opportunities to optimize sponsor, CRO, and site collaborations.
Providing patients with more flexibility in how they choose to participate in trials.
Higher costs headline list of new challenges faced by CROs and sponsors.
Five strategies to reduce risk and achieve deadlines.
As many countries slowly progress with the “New Normal,” researchers and healthcare providers are assessing digital/virtual approaches that could reinstate clinical trials.
Tips and best practices for empowering professionals to become change agents in their institutions, including clinical trials.
Past decades have shown gender-based differences in clinical trial results are often overlooked when considering safety and effectiveness.
The ACT EU initiative aims to develop the European Union further as a competitive center for innovative clinical research.
Biotechs can successfully overcome bottlenecks in time-to-market for new drugs by embracing contracting innovations with the same passion applied to research breakthroughs.
Wed, Sep 7, 2022 11:00am EST | 8:00am PST | 4pm BST | 5:00pm CEST Decentralized Clinical Trials (DCT) is one of the hottest buzzwords in Life Sciences and Connected Health organizations today. Like any new approach, challenges and roadblocks are common and knowing how to solve for them will empower your organization to accelerate your trial deployment, speeding return of results and time to market.
Involvement of clinical endpoint committees in the adjudication process can improve reliability and robustness of data.
2020 Tufts CSDD – IBM Watson Health benchmarking study highlights need for new functionality from EDC solutions and providers.
How innovative trial designs and advanced imaging modalities can address the challenges of early drug development to optimize outcomes for patients with solid tumors.
The DCT-driven evolution requires new levels of understanding and expertise.
Implementing new strategies with the use of patient-reported outcomes.
Study by Tufts CSDD uncovers potential reasons behind CRA shortages, turnover, experience requirements, and more.
Sponsors and CROs that work with these sites can better reach marginalized communities.
How to leverage novel trial designs and real-world data to support a cancer drug submission with an evidence strategy that is both approvable and reimbursable.
Advancing risk-based auditing one step further by identifying the underlying process deficiencies to enable improved corrective and preventive actions.
Presenting how data transformation is measured as part of the SAFE Data Standard, which data variables influence the rating and, how the appropriate level of data transformation is calculated.
Regulators are urging the use of data monitoring committees to support clinical trial management and decision-making during pandemic.
In this Q&A with Applied Clinical Trials' sister brand, Pharmaceutical Executive, Lofaso discusses marketing strategies for early-stage biotech companies, including how they can effectively recruit patients for their clinical trials.
Laboratory services organization focuses on easing patient and site burden with improved collection device.
Study seeks to understand how different forms of data meet the needs of researchers.
CRO-sponsor relationships are key as industry moves towards new age of outsourcing.